These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 11138685

  • 21. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC, Suleiman S, Pereira M, Rubin AD, Goldenberg DM.
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [Abstract] [Full Text] [Related]

  • 22. Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients.
    Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van Dongen GA, Boellaard R.
    J Nucl Med; 2009 Nov; 50(11):1828-36. PubMed ID: 19837762
    [Abstract] [Full Text] [Related]

  • 23. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D, Holdford D, Dawson K, Dinardo L, Reiter E.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):374-87. PubMed ID: 15380569
    [Abstract] [Full Text] [Related]

  • 24. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Blumenthal RD.
    J Nucl Med; 2003 Jan 01; 44(1):67-76. PubMed ID: 12515878
    [Abstract] [Full Text] [Related]

  • 25. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey RM, Hajjar G, Yeldell D, Brenner A, Burton J, Rubin A, Goldenberg DM.
    J Nucl Med; 2005 Apr 01; 46(4):620-33. PubMed ID: 15809485
    [Abstract] [Full Text] [Related]

  • 26. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
    Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6064-72. PubMed ID: 17062682
    [Abstract] [Full Text] [Related]

  • 27. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.
    Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ, Stigter-van Walsum M, Snow GB, van Dongen GA.
    Cancer Biother Radiopharm; 2003 Aug 15; 18(4):655-61. PubMed ID: 14503961
    [Abstract] [Full Text] [Related]

  • 28. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
    Wong JY, Thomas GE, Yamauchi D, Williams LE, Odom-Maryon TL, Liu A, Esteban JM, Neumaier M, Dresse S, Wu AM, Primus FJ, Shively JE, Raubitschek AA.
    J Nucl Med; 1997 Dec 15; 38(12):1951-9. PubMed ID: 9430476
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Jan 15; 37(1):38-41. PubMed ID: 8543998
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics.
    van Gog FB, Visser GW, Klok R, van der Schors R, Snow GB, van Dongen GA.
    J Nucl Med; 1996 Feb 15; 37(2):352-62. PubMed ID: 8667076
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma.
    Postema EJ, Raemaekers JM, Oyen WJ, Boerman OC, Mandigers CM, Goldenberg DM, van Dongen GA, Corstens FH.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3995S-4002S. PubMed ID: 14506199
    [Abstract] [Full Text] [Related]

  • 36. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.
    Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, Paleologos N, Fredericks RK, Schold SC, Bigner DD.
    Clin Cancer Res; 1996 Jun 01; 2(6):963-72. PubMed ID: 9816257
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM.
    J Nucl Med; 1999 Oct 01; 40(10):1609-16. PubMed ID: 10520699
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.